Author/Authors :
namazi, s. Department of Pharmacotherapy - Faculty of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , masoomi, a. Department of Pharmacotherapy - Faculty of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , behdad , n. Department of Pharmacotherapy - Faculty of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , kojuri, j. Faculty of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , azarpira, n. Transplant Research Center - Shiraz University of Medical Sciences - Shiraz, Iran
Abstract :
Atorvastatin is prescribed for the primary and the secondary prevention of coronary artery diseases.
A wide variation in inter-individual statin response suggests that genetic differences may contribute to this
variation. This study investigated the association of ABCB1 (C3435T) and ABCC1 (G2012T) polymorphisms with
clinical response to atorvastatin in Iranian primary hyperlipidemic patients. Methods: Individuals (n=179) with
primary hypercholesterolemia were enrolled, and peripheral blood samples were collected. Genotyping of two
polymorphisms were performed by amplification refractory mutation system PCR. Results: Following four weeks
of treatment, a significant reduction of LDL-C was observed in variant groups (CT+TT) of ABCB1 (P=0.018) and
wild-type group (GG) of ABCC1 genes (P=0.029). Logistic regression analysis revealed a significant difference
between male and female responses to 10 mg/day atorvastatin (P=0.004, odds ratio=0.2, CI 95%=0.06-0.6).
Conclusion: Our finding indicated that these polymorphisms may be attributed to LDL-C serum levels in the
primary hypercholesterolemia patients receiving atorvastatin.
